ГОСТ ISO 10993-16-2016
degradation, absorption and excretion of PCL-based-implant, Biomaterials, 27,
pp. 1735-1740,2006
[62] LIPSCOMB, J.C. and OHANIAN, E.V. (eds.) .Toxicokinetics and risk assessment,
Informa, 2006
[63] CLAYSON,D.B., et al. (eds.).Toxicology, Elsevier, New York, 1996
[64] TOZER, T.N. and ROWLAND, M., Introduction to Pharmacokinetics and
Pharmacodynamics — The Quantitative Basis of Drug Therapy, Lippincott,
WILLIAMS & WILKINS, 2006
[65] VENKATAKRISHNAN, K., VON MOLTE, L.L. and GREENBLATT, D.J., Human
drug metabolism and cytochromes P450: Application and relevance of in vitro
models, J. Clin. Pharmacol., 41, pp. 1149-1179,2001
[66] WALKER, D.K., The use of pharmacokinetic and pharmacodynamic data in the
assessment of drug safety in early drug development, Br. J. Clin. Pharmacol.,58,
pp. 601-608,2004
[67] YACOBI, A., SKELLY, J.P., and BATRA, V.K., Toxicokinetics and new drug
development, Pergamon Press, 1989
[68] YAN, Z. and CALDWELL, G.W., Metabolism profiling, and cytochrome P450
inhibition & induction in drug discovery, Curr. Top. Med. Chem., 1, pp. 403-425,
2001
[69] YANNAS, I.V., Synthesis ofTissues and Organs, Chem. Bio. Chem., 5, pp. 26-39,
2004
[70] ZHOU, S., et al., Drug bioactivation, covalent binding to target proteins and
toxicity relevance, Drug Metab. Rev., 37, pp. 41-214,2005
20